pHLOGISTIX LLC Information

Developing point of care concussion diagnostic, and therapeutics which harness proprietary neuroinflammatory insights and technology. pHLOGISTIX has developed two technologies that will significantly change the way concussion and mild to moderate traumatic brain injury (mTBI) are diagnosed and treated. Currently there are no biomarker-based assays for detecting mTBI and treatment options are limited to symptom management. The diagnostic is a mobile-enabled point of care device, which incorporates the blood test and clinical data collected at various intervals for baseline and post-injury monitoring. The pHLOGISTIX diagnostic device, DXPH-901, utilizes advanced micro-fluidics and genetic array technology to detect specific proteins in the blood that are uniquely attributable to neurological trauma. Preclinical data in animal models has convincingly demonstrated the viability of this approach. We are ready to begin clinical studies and pursue the 510(k) path toward US FDA regulatory approval. Our companion therapeutic candidate, TXPH-301, has completed preliminary manufacturing testing, and is ready for final preclinical testing in validated animal models. TXPH-301 harnesses beneficial attributes of the inflammatory cascade but inhibits factors which can exacerbate neurological trauma.